DGX vs TCRX · P/E 22, rev $5.94B vs rev $2.0M
Quest Diagnostics Incorporated (DGX) versus Tscan Therapeutics Inc (TCRX) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported TCRX revenue for 2026-06-30 was $2.0M. Net income was -$59.0M. TCRX currently screens at market cap $62.1M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. TCRX currently screens at market cap $62.1M.
Not investment advice. Open the DGX and TCRX stock pages for the full models.
Not investment advice.